There have been intensifying efforts to explore mobile health (mhealth) technologies for delivering healthcare at reduced costs and for facilitating more precise and personalized medicine[@b1][@b2][@b3] which have led to 73 apps endorsed (examples in [Table 1](#t1){ref-type="table"}, a complete list in [Supplementary Table S1](#S1){ref-type="supplementary-material"}) and additional ones reviewed[@b1] by the US Food and Drug Administration (FDA) for self-diagnosing acute diseases and monitoring chronic conditions[@b1] based on such physiological biomarkers as body temperature and brainwave[@b4][@b5], and such simple-analyte biomarkers as glucose and urine protein contents[@b4][@b5].

Although these physiological and simple-analyte biomarkers cover many disease conditions, their coverage is substantially limited for such prevalent diseases as cancers, infectious, respiratory, digestive, endocrine and nervous system diseases, as indicated by the disease-coverage profiles of the 73 FDA endorsed, and 94 physiological and simple-analyte biomarker candidates described in the literatures ([Fig. 1](#f1){ref-type="fig"}, [Table 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, [Supplementary Table S1](#S1){ref-type="supplementary-material"} and [S2](#S1){ref-type="supplementary-material"}). Apart from the development of more portable biomarker detection technologies, additional biomarkers are needed for fulfilling the tasks of mhealth technologies as efficient and effective means for providing wider coverage of healthcare and personalized treatments at reduced costs[@b1][@b2][@b3].

Some genetic, proteomic and metabolomic molecular biomarkers have been clinically used and many more such molecular biomarker candidates (hitherto also tentatively named biomarkers) have been discovered for diagnosing and monitoring diseases, directing treatments and predicting patient responses[@b6][@b7][@b8]. Of immediate relevance to mhealth are the hundreds of literature-reported non-invasive and minimally-invasive diagnostic, prognostic and theragnotic molecular biomarkers from such non-invasive sources as urine, breath, saliva, tear, feces, sputum and oral mucosa samples (Examples in [Table 3](#t3){ref-type="table"} and complete list in [Supplementary Table S3](#S1){ref-type="supplementary-material"}) and from such minimally-invasive sources as finger-prick (the list of serum biomarkers potentially detectable from finger-prick is in [Supplementary Table S4](#S1){ref-type="supplementary-material"}), which significantly expand the disease coverage as indicated by the disease-coverage profiles of the 664 (27 clinical trial) non-invasive and 592 serum (69 clinical trial or use) molecular biomarkers with respect to those of 73 FDA endorsed apps and 94 physiological and simple-analyte biomarkers ([Fig. 1](#f1){ref-type="fig"}). Many biomarkers are detectable by the new biomarker-detection technologies that become increasingly portable, faster, user-friendly, inexpensive and accurate[@b9][@b10][@b11], some of which have been explored for potential mhealth applications[@b9][@b12][@b13][@b14][@b15].

From the investigations and opinions described in the literatures listed in [Supplementary Table S3](#S1){ref-type="supplementary-material"}, there are good reasons to speculate the readiness of some of these technologies for mhealth applications. But before the acceptance and widespread utilization of these technologies, several key questions need to be answered or resolved. Apart from the development of more portable biomarker detection technologies, an important question is whether the new portable biomarker detection technologies are sufficiently sensitive, fast, convenient and inexpensive for biomarker detection in the typical mhealth settings (low sample volume and biomarker concentrations). Another question is whether the discovered and investigative molecular biomarkers extracted from the non-invasive and minimally invasive sources are relevant to mhealth applications in terms of the detection accuracies and the coverage of disease conditions and patient populations. The third is how to resolve the different readings generated from different mhealth devices and variations in individual operations. The fourth is how to manage the heavy workload in processing and analysing the big data arising from widespread use of mhealth devices.

Here, we address some of these questions by analysing (1) biomarker detection capability of the literature-reported new technologies with specific focus on their detection sensitivity, required sample volume, test time, and costs with respect to experimentally-determined biomarker levels in patients and the detection limits, and (2) the disease coverage, patient populations, and the diagnostic, prognostic, and theragnostic sensitivity and specificity of the literature-reported non-invasive and minimally-invasive finger-prick molecular biomarkers for mhealth applications with respect to the detection limits of the new detection technologies. We also discuss the feasibility and practical issues of adopting a new strategy for reducing the heavy workload of mhealth data processing by automated electronic pre-screening of the big biomarker screening data.

Literature Search
=================

The detailed information of 73 mhealth apps endorsed by the US FDA was obtained by manually checking the descriptions of the apps listed in FDA 510(k) medical device database[@b16]. The physiological and molecular biomarkers were obtained by the comprehensive literature search of the Pubmed database by using the combination of the keyword "biomarker" together with one of the keywords of "clinical", "patient", "disease", "drug", and specific disease names such as "cancer", "inflammation" and "hypertension". We also searched and evaluated biomarker review papers from reputable journals by using the combination of the keywords "biomarker" and "review", with the cited original articles checked to collect detailed information about the discussed biomarker, such as the name, source, specific disease and function, specificity and sensitivity of the biomarker. The detailed information of these 254 evaluated review and research papers are listed in [Supplementary Table S6](#S1){ref-type="supplementary-material"}. Additional sources such as the abstracts of the American society of clinical oncology were also systematically searched, with 658 biomarker conference abstracts in 1995--2013 extracted and evaluated by data mining and manual curation. Non-invasive biomarkers were selected if they were detected in non-invasive tissues such as urine, breath, saliva, tear, feces, sputum and oral mucosa samples. The information of disease conditions was searched from the websites of professional medical associations such as WHO[@b17] and American Cancer Society[@b18], and such additional sources as reputable books and review articles, using combinations of keywords such as the disease name and "prevalence" or "incidence". These biomarkers were organized based on their international classification ICD-10 codes[@b19] and were displayed with respect to these codes in a tree graph by using the automatic tree generator module in iTOL[@b20].

The performance of the biomarkers in diagnosing, prognosing or theragnosing specific conditions has been statistically measured by sensitivity (the proportion of the condition-positive samples that are correctly identified as positive) and specificity (the proportion of the condition-negative samples that are correctly identified as negative)[@b21]. Wherever reported in the literature, these statistical performance measures were recorded. Apart from the collection of the biomarker detection technologies described in our searched biomarker literatures, additional literature search was conducted for searching biomarker detection technologies of potential mhealth applications by using the keyword "biomarker" in combination with one of the keywords "detection", "detector", "device", "technology", "technique" and "assay". These detection technologies were analysed for selecting those with potential mhealth applications based on their detection performance, portability, detection time, cost and ease of use.

New technologies for detecting non-invasive molecular biomarkers and their relevance to mhealth
===============================================================================================

The new biomarker-detection technologies combined with mobile phone or the equivalent imaging devices have been explored for detecting at least 23 molecular biomarkers including 11 non-invasive ones ([Table 4](#t4){ref-type="table"}). These new technologies can be categorized into four groups: (1) paper-based and mobile phone enabled, (2) paper-based, (3) mobile-phone enabled, and (4) the other point of care technologies. The first group of technologies combines innovative paper-based microfluidic analytical technologies with mobile phone enabled automated image processing tools, which are most relevant to mhealth applications because of the very low cost (\~\$2.60+ cost plus mobile phone), increasingly enhanced detection sensitivity (0.3--60 ng/mL, 0.13--21.3 μg/mL and 0.81--2000 ng/mL for small molecule, peptide and protein biomarkers respectively), low sample volumes (0.5--25 μL), short detection time (15--60 mins), and the convenient biomarker processing (mobile phone-based) capabilities. The recently developed paper-based microfluidic analytical technologies include paper-based enzyme-linked immunosorbent assays (P-ELISA)[@b9][@b22], paper lateral flow immunoassays (P- LFIAs)[@b12][@b23], and paper-based Au-nanoprobes[@b22]. These are integrated with or coupled to mobile phones equipped with the colorimetric algorithms[@b22] and the applications for immediate data processing of the detection results without referring to peripheral equipment for read-out and analysis[@b9].

The second group of technologies primarily employ innovative P-ELISA in combination with a scanner, printer or digital camera based image-processing facility to achieve a detection sensitivity as high as 33.7 fg/mL[@b24] and 18 pM/mL[@b25] for detecting peptide and protein biomarker respectively. The imaging processing component of these technologies may be potentially replaced by mobile phone-based ones for potential mhealth applications. The third group of technologies integrates mobile phone imaging processing tools with newly developed disposable microfluidic chip[@b26], opto-acoustic immunoassay[@b27], microfluidic capillary array equipped with optical signal amplifier[@b28], microtiterplate based ELISA[@b29] and other technologies. These technologies achieve detection sensitivity up to the level of 60--300 pg/mL for protein biomarkers[@b29][@b30]. Although their costs are more suitable for point of care (POC) rather than mhealth applications, the innovative design may be potentially implemented into paper-based platforms for more extensive mhealth applications. A new POC technology in the fourth group, the negative-pressure-driven microfluidic chip magnetic bead based ELISA, is capable of detecting a small molecule biomarker at sensitivity level of 0.3 ng/mL[@b31][@b32]. If implemented into paper-based and mobile phone-enabled platforms, this technology may potentially find wider applications for detecting small molecule biomarkers in mhealth.

Overall, 12 or 52.2% of the 23 tested molecular biomarkers are detectable by these new technologies at low concentrations (0.3--810 pg/mL and 4--50 ng/mL for 8 and 4 biomarkers respectively). Although the detectable concentrations of these 23 biomarkers are roughly 10-fold higher than those of the conventional technologies[@b24], seven of them are nonetheless within the lower detection limit of the new technologies for non-invasive detection[@b24][@b27]. Of the eight biomarkers with available patient data, only two biomarkers in the corresponding non-invasive source are outside the detection limit of the new technologies. Moreover, 64.3% of these biomarkers are detectable at significantly lower sample volumes (0.5--12 μL) and shorter time (10--60 min) than the volumes (100--300 μL)[@b13][@b25] and durations (up to 4h)[@b24] of the conventional technologies. The costs of these detection devices are \~\$300--\$600 US dollars[@b33]. The per-test costs are in the range of 0.01--190. Therefore, the new technologies are fairly sensitive, efficient, and inexpensive for detecting a substantial percentage of the tested non-invasive biomarkers, and there is high likelihood that they can be applied for detecting other non-invasive biomarkers in mhealth applications.

The non-invasive molecular biomarkers and their relevance to mhealth
====================================================================

Analysis of the 664 literature-reported non-invasive molecular biomarkers (examples in [Table 5](#t5){ref-type="table"} and a complete list in [Supplementary Table S5](#S1){ref-type="supplementary-material"}) showed that 546 and 183 biomarkers are for the diagnosis and prognosis of 85 and 45 disease conditions respectively, with 31 and 14 (or 36.5% and 31.1%) of the disease conditions covered by higher number (4--22) of biomarkers and 10 and 6 (or 11.8% and 13.3%) of the disease conditions by clinically-validated/evaluated biomarkers. Among these, 21 acute diseases and 11 chronic conditions affect large populations of 239,000--235 million and 10--235 million people respectively. Therefore, exploration of these biomarkers may significantly improve the efficiency of the management of these disease conditions.

The diagnostic performance of 88 (or 29.7%) of the 296 diagnostic biomarkers for 43 diseases and the prognostic performance of 24 (25.5%) of the 94 prognostic biomarkers for 14 conditions have been reported in the literature (examples in [Tables 3](#t3){ref-type="table"} and [5](#t5){ref-type="table"} and a complete list **in** [Supplementary Table S3](#S1){ref-type="supplementary-material"}, [S5](#S1){ref-type="supplementary-material"}) Their performances have been typically measured by sensitivities (the rates for positive identification of disease conditions) and specificities (the rates for correct classification of the negatives). The sensitivities and specificities of the majority of these biomarkers are ≥85% and ≥80% for diagnosis, and ≥80% and ≥80% for prognosis respectively, which are roughly at the ≥90% sensitivity and ≥90% specificity levels of the good biomarkers[@b21]. Therefore, a substantial percentage of these non-invasive biomarkers are expected to be potentially useful for pre-screening patients in need of further evaluations in mhealth applications.

The utility of these biomarkers for mhealth applications also depends on whether they are detectable by the new detection technologies, i.e., whether the levels of these biomarkers in the non-invasive sources from the patients are within the detection range of the new detection technologies. We searched from the literatures the corresponding biomarker levels for 35 diseases ([Supplementary Table S5](#S1){ref-type="supplementary-material"}, examples in [Table 5](#t5){ref-type="table"}) and compared them to the detection limits of the new technologies. Our analysis showed that 26 (or 74.3%) of the 35 disease conditions with searchable information, including 8 disease conditions with large patient populations, have one or more biomarker detectable by the new technologies ([Table 5](#t5){ref-type="table"}), suggesting that a substantial percentage of the disease conditions including those with large patient populations may be partly covered by the new technologies.

The potential of the minimally invasive finger-prick biomarker technologies for mhealth applications
====================================================================================================

The minimally invasive finger-prick biomarker technologies have been developed for POC applications[@b11]. Because of their improved detection performance[@b34], portability[@b35] and ease of use[@b36], and because of their decreased detection time[@b34], some of these technologies when combined with smartphone-based processing technologies may find potential mhealth applications. Serum biomarkers are known to be detectable at finger-prick albeit at altered concentrations and thus at re-adjusted detection cut-off values[@b37][@b38]. Therefore, one can hypothesize that most of the serum biomarkers of sufficient level of concentrations may be potentially detectable by finger-prick biomarker technologies. The application of these technologies in mhealth significantly expands the coverage of disease conditions because some biomarkers not found in urine are in the serum (e.g. it has been reported that the blood contains the common markers of liver function that are not found in urine[@b35]). Our own literature search results showed that the literature-reported serum biomarkers and biomarker candidates cover additional 62 disease conditions beyond those covered by the existing physiological, simple-analyte, and the non-invasive molecular biomarkers and biomarker candidates ([Fig. 1](#f1){ref-type="fig"} and [Supplementary Table S4](#S1){ref-type="supplementary-material"}).

Moreover, the finger-prick biomarker technologies can potentially have more enhanced capabilities in detecting the biomarkers of low concentrations. The levels of biomarkers in blood are typically more concentrated than those biomarkers collected from the non-invasive urine, breath, saliva, tear, feces, sputum or oral mucosa sources{Song, 2014 \#89} {Abdalla, 2012 \#115}. For those biomarkers with concentrations in the non-invasive and finger-prick sources below and above the detection limit of the mhealth biomarker technologies respectively, some of them are potentially detectable by using finger-prick biomarker technologies even if they are undetectable by the non-invasive biomarker technologies.

Several new technologies have been developed with potential applications for detecting serum biomarkers from a drop of blood ([Table 4](#t4){ref-type="table"}). To enable the purification and detection of serum biomarkers, specially designed fluid handling and silver reduction devices have been combined with the ELISA microfluidic chip for simplified biomarker detection, which enables the detection of an HIV biomarker from 1 μl of unprocessed whole blood in \<15 min[@b39]. In another design, a microfluidic purification chip was developed for simultaneously capturing multiple biomarkers from blood samples and releasing them into purified buffer for sensing by a silicon nanoribbon detector, which was able to detect two model cancer antigens from a 10 ml sample of whole blood in \<20 min[@b40]. A micropatterned paper device that combines a filter membrane and a patterned paper chip for achieving blood plasma erythrocyte separation and biomarker detection from the blood from a fingerstick, which is capable of detecting protein biomarkers at \~50 g/L concentrations[@b35]. Progress has been made in developing plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye with the ability to detect biomarkers in whole serum at the ultralow concentration of 10^−18^ g mL^−1^ [@b41].

We have found the reports about the detection of 12 serum biomarkers by means of these new technologies ([Table 4](#t4){ref-type="table"}). Overall, 5 or 42% of the 12 biomarkers are detectable at concentrations of \<1.5 ng/mL. Considering that many serum biomarker concentrations are higher than those collected from the urine or other non-invasive sources, the relevant technologies may be extended for the detection of a more variety of low concentration biomarkers than those coverable by the non-invasive biomarker technologies. These technologies enable serum biomarker detection mostly at low sample volumes of 1--10 uL and short time of 12--30 min comparable to those of the non-invasive biomarker technologies. The cost of a microtiterplate based ELISA device coupled with a smartphone is \<\$660[@b29]. The per test costs of these technologies are in the range of \$0.1--34. Three studies reported the sensitivity and specificity of five serum biomarkers, which are in the range of 82--100% (vast majority \>90%) and 78%-100% respectively[@b38][@b39][@b42]. Therefore, these new technologies are fairly sensitive, efficient, and inexpensive for detecting a substantial percentage of the tested serum biomarkers with potential mhealth applications.

Coping with the heavy workload in mhealth: Feasibility of automated electronic pre-screening of big mhealth data
================================================================================================================

There are concerns about the increased workload in processing and analysing the big data arising from widespread use of mhealth devices[@b1]. On the hand, mhealth devices as digital tools may conveniently facilitate electronic pre-screening of the biomarker readings for filtering potential patients likely in need of further attention and evaluation, which helps to significantly reduce the workload. A digitally-coded biomarker, disease and therapeutic information processing system may be developed for automatically receiving, processing, pre-screening, and dispatching the biomarker readings transmitted from mhealth devices ([Fig. 2](#f2){ref-type="fig"}).

It is feasible to develop such a system using available tools such as the International Classification of Diseases (ICD) codes for defining, studying and managing diseases and treatments[@b43], the Systematized nomenclature of medicine for clinical documentation and reporting[@b44], the Unified medical language system for biomedical terminology[@b45], the Therapeutic target database biomarker and target information and links to the ICD and drug codes[@b46], and the Drugbank drug information[@b47]. Further efforts are needed for additional information refinement and integration, determination and clinical validation of biomarker pre-screening thresholds, and development and education of testing protocols. There are also potential issues arising from missed detection or misidentification by an electronic system, lack of data security and insufficient regulation standards.

Concluding Remarks
==================

Molecular biomarker-based mobile health technologies have the potential to significantly improve the efficiency and quality of healthcare for a variety disease conditions particularly those with large patient populations that cannot be solely covered by physiological and simple-analyte biomarkers. Some of these biomarkers combined with the new detection technologies are readily applicable for mhealth applications. The increased workload in processing and analyzing high volumes of mhealth data may be efficiently managed by an electronic system that facilitate automatic pre-screening and analysis of the biomarker data for filtering potential patients likely in need of further attention and evaluation.
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###### Examples of FDA endorsed mobile apps. (For a complete list, please refer to [Supplementary Table S1](#S1){ref-type="supplementary-material"}).

  **Device Name**                                                                                **Applicant**               **510(k) Number**    **Type**                                                         **Measure**                                                            **Disease**
  ---------------------------------------------------------------------------------- -------------------------------------- ------------------- ------------- --------------------------------------------------------------------------------------------------------------------- -----------------------
  Airstrip Ob                                                                              Airstrip Technologies, Lp              K090269        Monitoring                                    Fetal Heart Tracings; Maternal Contraction Pattern                                    Obstetrics/Gynecology
  Alivecor Heart Monitor For Iphone                                                              Alivecor, Inc.                   K122356        Monitoring                                                            Ecg                                                              Cardiovascular
  Beam Brush/Beam App                                                                        Beam Technologies, Llc               K121165        Monitoring                                                    Brushing Usage Data                                                        Tooth Decay
  Bodyguardian System Bodyguardian Control Unit Bodyguardian Connect                            Preventice, Inc.                  K121197        Monitoring                                        Ecg; Activity; Heart Rate; Respiration Rate                                          Cardiovascular
  Cg-6108 Arrhythmia Ecg Event Recorder                                               Card Guard Scientific Survival, Ltd.        K060911        Monitoring                                                            Ecg                                                            Cardiac Arrhythmia
  Customized Sound Therapy (Cst)                                                        Tinnitus Otosound Products, Llc           K070599         Treatment                                                                                                                                Tinnitus
  Freestyle Tracker Diabetes Management System                                             Abbott Diabetes Care Inc.              K020866        Monitoring                                                          Glucose                                                               Diabetes
  Fully Automatic Wireless Blood Pressure Wrist Monitor                                      Andon Health Co., Ltd                K121470        Monitoring                                                      Blood Pressure                                                         Cardiovascular
  Iglucose System                                                                            Positiveid Corporation               K111932        Monitoring                                                          Glucose                                                               Diabetes
  Intuition                                                                                     Terarecon, Inc.                   K121916        Data Viewer                                                Ebt, Ct, Pet Or Mri Image                                                           
  Kd-936 Fully Automatic Wireless Blood Pressure Monitor                                      Andon Health Co.,Ltd                K120672        Monitoring                                                      Blood Pressure                                                          Cardivascular
  Medicalgorithmics Real-Time Ecg Monitor And Arrhythmia Detector, Model Pocketecg        Medicalgorithmics Sp Z.O.O.             K090037        Monitoring                                             Heart Beat, Rhythm Abnormalities                                                 Cardivascular
  Mobile Mim                                                                                   Mim Software Inc.                  K112930        Data Viewer                                        Spect, Pet, Ct, Mri, X-Ray And Ultrasound                                                   
  Myglucohealth Glucose Monitoring Systems                                                 Entra Health Systems, Ltd.             K081703        Monitoring                                                          Glucose                                                               Diabetes
  Myvisiontrack(Tm)                                                                    Vital Art And Science Incorporated         K121738        Monitoring                                   Central 3 Degrees Metamorphopsia (Visual Distortion)                                        Maculopathy
  Proteus Ingestion Confinmation Systems                                                    Proteus Biomedical, Inc.              K113070        Monitoring    Physiological And Behavioral Metrics Including Heart Rate, Activity, Body Angle And Time-Stamped User-Logged Events          General
  Rhythmstat Xl                                                                               Data Critical Corp.                 K971650        Diagnostic                                                            Ecg                                                              Cardiovascular
  Sd360 Digital Recorder/Sd360 Holter Digital Recorder                                     Northeast Monitoring, Inc.             K041901        Monitoring                                                        Heart Beat                                                           Cardiovascular
  Silhouette, Model 1000.01                                                                  Aranz Medical Limited                K070426        Monitoring                                                      External Wounds                                                        External Wounds
  Smartheart                                                                          Shl Telemedicine International Ltd.         K113514        Monitoring                                                 Lead Egg And Rhythm Strip                                                   Cardiovascular
  Veo Multigas Monitor For Pocket Pc, Model 400221                                            Weissburg Associates                K051857        Monitoring                                                  Carbon Dioxide; Oxygen                                                     Anesthesiology
  Vestibular Analysis Apparatus                                                               Capacity Sports, Llc                K121590        Monitoring                                                          Balance                                                                    
  Welldoc Diabetes Manager System And Diabetes Manager Rx System                                  Welldoc, Inc                    K120314        Monitoring                                                          Glucose                                                               Diabetes
  Withings Blood Pressure Monitor                                                                   Withings                      K110872        Monitoring                                                      Blood Pressure                                                         Cardiovascular

###### Examples of physiological biomarkers. (For a complete list of physiological biomarkers, please refer to [Supplementary Table S2](#S1){ref-type="supplementary-material"}).

  **Biomarker**                                               **Biomarker Type**                  **Detected Disease**               **Disease ICD Code**   **Clinical status**
  ------------------------------------------------------- -------------------------- ---------------------------------------------- ---------------------- ---------------------
  Amygdala volume                                                 Prognostic                      Parkinson's disease                     G20, F02.3                  
  Ankle brachial index (ABI)                                      Diagnostic                  Peripheral arterial disease                    I73              Used in clinic
  Anterior temporal atrophy                                       Diagnostic               Frontotemporal lobar degeneration                G31.0                     
  Carotid intima-media thickness (CIMT)                           Diagnostic                        Coronary disease                        I25.1          
  Early hypertension                                             Theragnostic                      Pancreatic cancer                         C25              Clinical trial
  EBC pH                                                          Diagnostic                             Asthma                              J45                      
  Electrocardiography (ECG)                                       Prognostic                    Acute coronary syndrome                     I20.0          
  Hair morphology                                          Prognostic; Theragnostic              Mucopolysaccharidoses                       E76           
  Hippocampal volume                                              Prognostic                      Parkinson's disease                     G20, F02.3       
  Longitudinal MRI volumetric data                                Prognostic                      Alzheimer's disease                      G30, F00           Used in clinic
  Macrophage migration inhibitory factor (MIF)                    Diagnostic                   Bronchopulmonary dysplasia                   P27.1                     
  Mammographic density                                            Diagnostic                         Breast cancer                           C50              Clinical trial
  Mean width of frontal horns of lateral ventricles               Prognostic                      Parkinson's disease                     G20, F02.3                  
  Mean width of third ventricle                                   Prognostic                      Parkinson's disease                     G20, F02.3       
  Motor unit number estimation                                    Monitoring                 Amyotrophic lateral sclerosis                  G12.2          
  Neurophysiological index                                        Monitoring                 Amyotrophic lateral sclerosis                  G12.2          
  Sclerosis                                                       Prognostic                      Follicular lymphoma                        C82              Clinical trial
  Single-fiber electromyography (SFEMG)                           Prognostic                       Myasthenia gravis                        G70.0                     
  Sputum cytology                                                 Diagnostic                         Lung carcinoma                        C33-C34         
  Total kidney volume (TKV)                                       Prognostic          Autosomal-Dominant Polycystic Kidney Disease           Q61           
  Unilateral area of substantia nigra hyperechogenicity           Prognostic                      Parkinson's disease                     G20, F02.3       
  Urine osmolality                                                Prognostic          Autosomal-Dominant Polycystic Kidney Disease           Q61           
  Voxel-based morphometry                                         Diagnostic                 Amyotrophic lateral sclerosis                  G12.2          

###### Examples of non-invasive molecular biomarkers. For a complete list of non-invasive molecular biomarkers, please refer to [Supplementary Table S3](#S1){ref-type="supplementary-material"}.

  **Biomarker**                                    **Detected Disease (ICD code)**    **Type**    **S**   **Detection Sen**          **Detection Spe**                            **Biomarker**                     **Detected Disease (ICD code)**   **Type**   **S**   **Detection Sen**   **Detection Spe**
  ----------------------------------------------- --------------------------------- ------------ ------- ------------------- --------------------------------- --------------------------------------------------- --------------------------------- ---------- ------- ------------------- -------------------
  17-urine-peptide biomarker panel                             M00-M25                  Diag        U           \~85%                     \~100%                                 MEP1A, meprin A                                 M30.3                  Diag       U           \~93%               \~94%
  2-aminoacetophenone                                            E84                    Diag       Br           0.938                      0.692                         Methylhistamine; interleukin-6                     N30.10, N30.11              Diag       U            0.7                0.724
  8-hydroxy-2-deoxyguanosine (8-OHdG)                           P27.1                   Diag        U           0.857                      0.611                   Monoclonal free immunoglobulin light chains                   E85.8                  Diag       U           0.813               0.98
  ABCA5                                                         D07.5                   Diag        U          \~100%                       N/A                      Monocyte chemotactic protein-1 (MCP-1)                      Q62.0                  Diag       U          \~85.0%             \~90.0%
  Basic fibroblast growth factor                                 C56                    Diag        U            0.7                       0.75                         N-Acetyl-β-D-glucosamindase (NAG)                        N02.2                  Prog       U           0.77                 N/A
  Beta2-microglobulin                                           N15.0                   Diag        U           0.723                      0.844                Neutrophil gelatinase-associated lipocalin (NGAL)                 M32                   Prog       U           \~70%               \~89%
  Calprotectin                                                 K50,K51                  Prog        F            0.9                       0.83                                                                                  N14.1                  Prog       U            0.8                0.75
  DPD                                                           C90.0                   Diag        U           0.889                      0.833                                       B20                                    Moni; Ther                 U       0.94          0.71         
  EL, endothelial lipase protein                                 C16                    Diag        U           0.79                         1                                         N17                                       Diag                    U         1           0.98         
  Eosinophils                                                    J45                    Diag       Sp           0.86                       0.88                                       N14.1                                      Diag                    U       0.73            1          
  Fibrinopeptide B                                           I82.4,I82.5                Diag        U             1                        0.85                                        NGF                                  N30.10, N30.11              Diag       U           0.75                0.655
  Fibulin-3                                                  M15-M19,M47                Diag        U           0.746                      0.857                                   Orosomucoid                                  O11,O14                 Prog       U          \~56.0%             \~73.0%
  HLA-DR                                                        T86.1                   Diag        U            0.8                       0.98                                Podocalyxin (PODXL)                                C64                   Diag       U             1                   1
  IL-18                                                          N17                    Prog        U           \>90%                      \>90%                         Pyruvate kinase isoenzyme M2-PK                        C18-C21                 Diag       F          73--83%              0.82
  IL-8                                                         F40-F42                  Diag        U          \~100%                       N/A                                      S100A12                                    K50,K51                 Diag       F           0.86                0.96
                                                             N21.0-N21.9             Diag; moni     U            0.9                       0.68                                   S100B protein                                   S06                   Prog       U            0.9                0.628
                                                                                                                              S100B; lactate/creatinine ratio                         G93.4                                      Diag                    U       0.99          0.97                   
  Kininogen                                                     B55.0                   Diag        U            0.9                                                                  Tim-3                                      T86.1                  Prog       U          84--87%             95--96%
  Lactoferrin                                                  K50,K51                  Moni        F         70--100%                   44--100%                                  Trypsinogen                                    K85                   Diag       U             1                 0.96
  Leucine-rich alpha-2-glycoprotein (LRG)                      K35-K37                  Diag        U           0.95                         1                        Trypsinogen activation peptide (TAP)                        K85                   Prog       U           0.917               0.897
  Liver-type fatty acid-binding protein(L-FABP)                 N03.2                Prog; Moni     U           0.875                      0.905                                  Trypsinogen-2                            K85, K86.0-K86.1             Diag       U           0.81                0.97
  Matrix metalloproteinase 9 (MMP 9)                           H16.229               Diag; Moni     T           0.85                       0.94                                    Uromodulin                                    N02.8                  Diag       U             1                   1
                                                                N13.7                Diag;Prog      U           0.812                      0.85                                                                                                                                                       

(Diag: Diagnostic, Prog: Prognotic, Mon, Monitoring, Br: Breath, F: Feces, Sa: Saliva: Sk: Skin, Sp: Sputum, T: Tears, U: Urine, Sen: Sensitivity. Spe: Specificity).

###### New biomarker detection technologies.

  **Information about the Biomarker used for Testing the Detection Technology**    **Information about the Biomarker Detection Technology**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------ -------------- ---------- ---------------------------------------------- ----------------------------- --------------
  Paper-based and mobile-phone enabled technologies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Human epididymis protein 4 (HE4)                                                                         Protein                                     Urine                                                   Ovarian cancer (D)                                                          364.5 ng/mL - 458.8 mg/mL                                  0.0574 ng/mL - 727.1 ug/mL                                                                   Paper-based ELISA + smartphone                                                                                          N/A                                                19.5 ng/mL          1250 ng/mL     100 μL             5 h (may be cut to 15 min)                   Within range              [@b9]
  Mycobacterium tuberculosis nucleic acids                                                                   DNA                                        N/A                                                     Tuberculosis (D)                                                                      N/A                                                         N/A                                                                          Paper-based Au-nanoprobes + smartphone                                                                                      N/A                                                 10 μg/mL              N/A          5 μL     65 min (2h30min including PCR amplification)               N/A                  [@b12]
  MMP9                                                                                                     Protein                                     Urine                                                 Colorectal cancer (D)                                                                    N/A                                                         N/A                                                                      Paper lateral flow assay + smartphone/scanner                                                                        \$2.60 + cost of cellphone                                     92 ng/mL           644 ng/mL       5 μL                         N/A                                    N/A                  [@b15]
  Thrombin                                                                                                 Protein                                     Urine                                                     Thrombosis (D)                                                                       N/A                                                         N/A                                                                      Paper lateral flow assay + smartphone/scanner                                                                        \$2.60 + cost of cellphone                                     72 ng/mL           504 ng/mL       5 μL                         N/A                                    N/A                  [@b15]
  Neuropeptide Y                                                                                           Peptide                                    Saliva                                         Post-traumatic stress disorder (P, T)                                                  ∼1.7--5.95 pg/mL(plasma)                    0.014--0.065 pg/mL (saliva), ∼0.21--2.42 pg/mL (plasma)                                        Paper-Based ELISA + camera/smartphone/scanner/printer                                                                             Low cost                                            127.59 ng/mL        21.265 μg/mL     3 μL                       \<60 min                            Out of range              [@b22]
  Hepatitis B virus plasmid DNA                                                                              DNA                                        N/A                                                     Hepatitis B (D)                                                                       N/A                                                         N/A                                                                    Convective polymerase chain reaction + smartphone                                                                                 N/A                                          30 copies per reaction       N/A          3 μL                        20 min                                  N/A                  [@b48]
  VEGF                                                                                                     Protein                            Inner eye aqueous humor   Proliferative diabetic retinopathy, age-related macular degeneration, retinal vein occlusion (D)   740.1 ± 267.7 pg/mL, 383 ± 155.5 pg/mL, 219.4 ± 92.1 pg/mL                      14.4 ± 8.5 pg/mL                                                                        Paper-based ELISA + Smartphone                                                                        Cost of paper-ELISA + cost of cellphone                              33.7 fg/mL           10 μg/mL       2 μL                        44 min                             Within range              [@b24]
  Paper-based technologies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Chorionic gonadotropin                                                                                   Protein                                     Urine                                                     Pregnancy (D)                                                                    \>2.5 ng/mL                                                 \<0.5 ng/mL                                                       Automated paper-based sequential multistep ELISA. + inkjet printing                                                                      Low cost                                             0.81 ng/mL          500 ng/mL      50 μL                      15--25 min                           Within range              [@b49]
  HIV-1 envelope antigen gp41                                                                              Protein                                     Serum                                                   HIV infection (P)                                                                      N/A                                                         N/A                                                                               Paper-based ELISA + scanner                                                                          Cost of paper-ELISA + \$100 for scanner                                 N/A                 N/A        \<20 μL                      \<60 min                                 N/A                  [@b25]
  Anti-Leishmania antibodies                                                                               Protein                                 Canine blood                                                Leishmaniasis (D)                                                                      N/A                                                         N/A                                                                               Paper-based ELISA + scanner                                                                          Cost of paper-ELISA + \$100 for scanner                               1 mg/mL               N/A        μL range                      60 min                                  N/A                  [@b12]
  Anti-NC16A autoimmune antibodies                                                                         Protein                                 Blister fluid                                             Bullous pemphigoid (D)                                                                   N/A                                                         N/A                                                                           Paper-Based ELISA + desktop scanner                                                                      Cost of paper-ELISA + \$100 for scanner                               3 ug/mL             50 μg/mL       2 μL                        70 min                                  N/A                  [@b50]
  Lactoferrin                                                                                              Protein                                     Tear                                                   Dry eye syndrome (D)                                                             0.13 ± 0.22 mg/mL                                           2.05 ± 1.12 mg/mL                                                An inkjet-printed microfuidic paper-based analytical device + digital camera                                           \$0.0131 per testing sheet + cost of digital camera                         5 ng/mL             50 ng/mL      2.5 μL                       15 min                      Within range after dilution   [@b13][@b51]
  Mobile-phone enabled technologies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Plasmodium falciparum histidine-rich protein 2 (PfHRP2)                                                  Protein                                 Serum, Saliva                                                  Malaria (D)                                                               17--1167 pg/mL (saliva)                                                0                                                             A disposable microfluidic chip + smartphone with embedded circuit                                                                         N/A                                                 16 ng/mL           1024 ng/mL     0.5 μL                       15 min                             Out of range           [@b26][@b52]
  Bacterial DNA                                                                                              DNA                                        N/A                                                 Bacterial infection (D)                                                                   N/A                                                         N/A                                                    A disposable micro?uidic chip with primers + a fluorescence detector + smartphone                                                             \$350-\$600                                      760 DNA copies per μL        N/A         30 μL                        30 min                                  N/A                  [@b33]
  Interferon-gamma                                                                                         Protein                                      N/A                                                 Latent tuberculosis (D)                                                       48.69 ± 28.78 pg/ml (blood)                                 12.99 ± 5.70 pg/ml (blood)                           An opto-acoustic immunoassay + mobile phone technologies ( surface acoustic wave transducer, CMOS camera, LED)                                                low cost                                            17.15 pg/mL         17.15 ng/mL      N/A                         10 min                             Within range           [@b27][@b53]
  Adenovirus DNA                                                                                             DNA                                        N/A                                                     Viral infection                                                                       N/A                                                         N/A                                            A microfluidic capillary array + an optical signal amplifier (multi-wavelength LEDs) + smartphone                                \$180 for capillary array + cost of LED and smartphone                      0.4 ug/mL            5 μg/mL       10 μL                         N/A                                    N/A                  [@b28]
  Cortisol                                                                                              Small molecule                                Saliva                                            Stress, anxiety, depression (D)                                                         20.7--37.3 ng/mL                                            0.4--14.1 ng/mL                                            Chemiluminescent lateral flow Immunoassay + smartphone with custom-designed 3D printer                                                            Low cost                                             0.3 ng/mL            60 ng/mL      25 μL                        30 min                             Within range           [@b54][@b55]
  N-terminal proBNP molecule                                                                               Peptide                                     Blood                                                  Heart failure (D,P)                                                               1076 ± 138 pg/mL                                             38 ± 4 pg/mL                         A disposable biomarker sensing element + HDR image acquisition technique + computer screen photo-assisted technique + smartphone                                         N/A                                                 60 pg/mL           3000 pg/mL     150 μL                       12 min                             Within range           [@b30][@b56]
  IL-6                                                                                                     Protein                                     Serum                                                       Cancer (P)                                                                   300- 3500 pg/mL                                               \<300 pg/mL                                                                                ELISA + smartphone                                                                                                N/A                                                 2 pg/mL               N/A          N/A                     2 hour 40 min                          Within range              [@b57]
  Albumin                                                                                                  Protein                                     Urine                                                   Kidney disease (D)                                                               \>30--300 ug/mL                                               \<30 ug/mL                                                              Fluorescent assay in disposable test tubes + smartphone                                                                     \$190 + cost of phone                                      5--10 μg/mL          200 μg/mL      25 μL                        5 min                              Within range              [@b26]
  Other lab-on-a-chip platform technologies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Apolipoprotein A1                                                                                        Protein                                     Urine                                                   Bladder cancer (D)                                                             207.3 -3754.7 ng/mL                                           \~ 10 ± 8 ng/mL                                      A negative-pressure-driven microfluidic chip magnetic bead based ELISA + optical measurment device                                        lower costs than conventional ELISA                                 10 ng/mL           2000 ng/ml    14.5 μL                       40 min                             Within range           [@b31][@b32]
  Minimally invasive finger-prick biomarker technologies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  C-reactive protein                                                                                       Protein                                     Blood                                        Prostate cancer, colorectal cancer (P),                                                    \>3 ug/mL (blood)                                           \<1 ug/mL (blood)                                                                 A microtiterplate based ELISA + smartphone                                                                                  \<\$660                                              0.3 ng/mL            81 ng/mL       N/A                        \<30 min                     Within range after dilution   [@b29][@b58]
  HIV-1 gp41 and HIV-2 gp36                                                                                Protein                                     Blood                                                   HIV infection (P)                                                                      N/A                                                         N/A                                                        A low-power, low-cost and compact smartphone dongle of microfluidic ELISA                                                          \$34 + + cost of cellphone                                     10 μg/mL              N/A          2 μL                        15 min                                  N/A               [@b59][@b60]
  N-terminal proBNP molecule                                                                               Peptide                                     Blood                                                  heart failure (D,P)                                                              1076 +\_ 138 pg/mL                                           38 +\_ 4 pg/mL                        A disposable biomarker sensing element + HDR image acquisition technique + computer screen photo-assisted technique + smartphone                                         N/A                                                 60 pg/mL           3000 pg/mL     150 uL                       12 min                             Within range           [@b30][@b56]
  Antibodies against HIV                                                                                   Protein                                     Blood                                                        HIV (D)                                                                           \>0                                                          0                                                                         A mobile microfluidic chip for immunoassay                                              \$0.1 per cassette + \$0.5 light-emitting diodes+ \$6 photodetector + cell phone            N/A                 N/A          1 uL                        20 min                             Within range              [@b39]
  Antibodies against Treponema pallidum                                                                    Protein                                     Blood                                                      syphilis (D)                                                                        \>0                                                          0                                                                         A mobile microfluidic chip for immunoassay                                              \$0.1 per cassette + \$0.5 light-emitting diodes+ \$6 photodetector + cell phone            N/A                 N/A          1 uL                        20 min                             Within range              [@b39]
  Prostate-specific antigen (PSA)                                                                          Protein                                     Blood                                                  Prostate cancer (D)                                                                  \>4 ng/mL                                                   \<4 ng/mL                                                         A microfluidic purification step + label-free nanosensor detection                                                                      low cost                                             1.5 ng/mL              N/A         10 uL                        20min                              Within range              [@b40]
  Carbohydrate antigen 15.3 (CA15.3)                                                                       Protein                                     Blood                                                   Breast cancer (D)                                                                   \>30 U/ml                                                   \<30 U/ml                                                         A microfluidic purification step + label-free nanosensor detection                                                                      low cost                                              15 U/mL               N/A         10 uL                        20min                              Within range              [@b40]
  Haemoglobin                                                                                              Protein                                     Blood                                                      Anaemia (D)                                                                         N/A                                                         N/A                                                                                                                                                                                                                                                                                                                                                                                      [@b38]
  Aspartate aminotransferase (AST)                                                                         Protein                                     Blood                                                  Tuberculosis/HIV (T)                                                                    N/A                                                      5−40 U/L                                                                    A paper-based, multiplexed microfluidic assay                                                                            \<\$0.10 per test                                           84 U/L               N/A         15 uL                        15 min                             Within range              [@b42]
  Alkaline phosphatase (ALP)                                                                               Protein                                     Blood                                                  Tuberculosis/HIV (T)                                                                    N/A                                                     30−120 U/L                                                                   A paper-based, multiplexed microfluidic assay                                                                            \<\$0.10 per test                                           53 U/L               N/A         15 uL                        15 min                             Within range              [@b42]
  Aspartate aminotransferase (AST)                                                                         Protein                                     Blood                                                     Hepatitis (D)                                                       Acute : \~400 U/L, Chronic: \~ 160 U/L                                    5−40 U/L                                                             A micropatterned paper-based microfluidic device + cellphone                                                                         low cost                                               44 U/L             400 U/L       15 uL                        15 min                             Within range              [@b35]
  Alkaline phosphatase (ALP)                                                                               Protein                                     Blood                                                  Liver conditions (D)                                                                    N/A                                                     30−120 U/L                                                            A micropatterned paper-based microfluidic device + cellphone                                                                         low cost                                               15 U/L             400 U/L       15 uL                        15 min                             Within range              [@b35]

###### Examples of common diseases covered by non-invasive molecular biomarkers. For a complete list, please refer to [Supplementary Table S5](#S1){ref-type="supplementary-material"}.

  **Disease or Disease Class**          **Disease ICD Code**                         **Disease Prevalence**                   **Biomarker Function Type**   **Biomarker Molecular Type (No of Biomarkers, No in clinical use or trial)**   **Biomarker Source**   **Feasibility of New Tech Based Biomarker Detection**   **Highest Biomarker Detection Sensitivity**   **Highest Biomarker Detection Specificity**   **Disease Form (Acute/ Chronic)**   **Biomarker Level in Patients**   **Biomarker Level in Normal Population**   **Technology Readiness for Detecting Biomarkers from Non-Invasive Sources from Patients**
  ------------------------------ ----------------------------------- ------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------ ---------------------- ------------------------------------------------------- --------------------------------------------- --------------------------------------------- ----------------------------------- --------------------------------- ------------------------------------------ -------------------------------------------------------------------------------------------
  HIV infection                                  B20                         World (35.3 M),USA (1.15 M),UK (2.2 M)                      Prog                                                  P (6)                                                U                                     ELISA                                             94.00%                                        71.00%                                     A/C                                N/A                                   N/A                                                                 N/A
                                                                                                                                         Ther                                                  P (6)                                                U                                     ELISA                                             94.00%                                        71.00%                                     A/C                                N/A                             0.2--146.7 ng/mL                                                     Within range
  Diabetic Nephropathy            E10.2, E11.2, E12.2, E13.2, E14.2              P:World (20% - 40% of diabetes)                         Diag                                                  P (7)                                                U                                     ELISA                                             81.40%                                        62.50%                                      C                         27.3 ± 3.3 ng/μmol                        0--25 ng/mg                                                        Within range
                                                                                                                                         Prog                                                  P (3)                                                U                                     ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Type 2 diabetes                                E11                           P:World (), USA (27.85M), Europe ()                       Diag                                                  P (11)                                               U                                     ELISA                                              \~91%                                         \~78%                                      C                         56.9 ± 19.45 μg/mL                      9.7 ±2.35 μg/mL                                                      Within range
                                                                                                                                         Prog                                                  P (3)                                                U                                     ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Chronic stress                               F40-F42                                   P:World (40 M)                                  Diag                                                P (1, CT)                                              U                                     ELISA                                             100.00%                                         N/A                                       C                          70.9 ± 19.2 pg/mg                      18.8 ± 32 pg/mg                                                      Out of range
  Parkinson's disease                            G20                           P:World (10 M),USA (1 M),UK (6.7 M)                       Prog                                                  Sm (1)                                               U                                                                                         N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Asthma                                         J45                          P:World (235 M),USA (25 M),UK (30 M)                       Diag                                         Sm (4), P (1), Cell (2)                                     Br, Sp                                  ELISA                                           73.6--86.0%                                     88.00%                                      C                                 N/A                                   N/A                                                                 N/A
                                                                                                                                         Prog                            Sm (2), P (1) Sm+P (1, CT), Cell (1), Sm+Cell (1)                        Br, Sp                                  ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Acute appendicitis                           K35-K37                              I:USA (680,000 per year)                             Diag                                                  P (9)                                                U                                                                                       95.00%                                        100.00%                                     A                           0.9--19.3 μg/mL                        0.1--0.8 μg/mL                                                      Within range
  Inflammatory Bowel Disease                   K50,K51                P:World (0.396% population),USA (1.4 M),UK (2.5--3 M)              Diag                                           P (12, CU 2), Sm (1)                                      Br, F                                   ELISA                                          80--98%, 94%                                  82--96%, 76%                                   C                          2.45 ± 1.15 ng/mg                     0.006 ± 0.03 ng/mg                                                         N/A
                                                                                                                                         Prog                                               P (16, CU 2)                                            F                                     ELISA                                        80--90%, 70--100%                             82--83%, 44--100%                                C                                 N/A                               8--213 μg/mg                                                            N/A
                                                                                                                                         Ther                                                  P (2)                                                F                                     ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Psoriasis                                      L40                          P:World (125 M),USA (7.5 M),UK (11 M)                      Diag                                         P (2), miR (4), cell (1)                                      Sk                                    ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Arthritis                                    M00-M25                       P:World (1% of population),USA (52.5 M)                     Diag                                                  P (17)                                               U                                                                                        \~85%                                        \~100%                                      C                        191.7--313.4 ng/mmol                  129.25 -486.85 ng/mmol                                                  Within range
                                                                                                                                         Prog                                                  P (1)                                                U                                     ELISA                                               N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Osteoarthritis                            M15-M19, M47                                P:World (26.9 M)                                 Diag                              P (3), Sm (1), Pep (1), Modified Pep (2, CT 1)                           U                                     ELISA                                             74.60%                                        85.70%                                      C                              191.4 pM                               144.4 pM                                                      Almost within range
                                                                                                                                         Prog                                    Sm (1), Pep (3), Modified Pep (2)                                  U                                                                                         N/A                                           N/A                                       C                                 N/A                                   N/A                                                                 N/A
  Acute kidney injury                            N17                       P:USA (1--7.1% of all hospital admissions)                    Diag                                            P (15, CU 2, CT 3)                                         U                                     ELISA                                       69--100%, 73--100%                                  85--98%                                     A                          50.5--205.9 ng/mL                      5.7--17.7 ng/mL                                                      Within range
                                                                                                                                         Prog                                               P (2, CT 1)                                             U                                     ELISA                                              \>90%                                         \>90%                                      A                            0--955 pg/mL                           0--173 pg/mL                                                       Out of range
  Urolithiasis                               N21.0-N21.9                       P:USA (7% of women and 12% of men)                        Diag                                                  P (3)                                                U                                     ELISA                                             90.00%                                        68.00%                                      C                        104.66 ± 159.70 pg/mg                   7.76 ± 8.90 pg/mg                                                     Out of range
                                                                                                                                         Prog                                                  P (1)                                                U                                     ELISA                                               N/A                                           N/A                                       C                        104.66 ± 159.70 pg/mg                   7.76 ± 8.90 pg/mg                                                     Out of range
  Interstitial cystitis                    N30.10, N30.11                            P:USA (8 million women)                             Diag                                              P (7), Sm (2)                                            U                                     ELISA                                             70.00%                                        72.40%                                      C                          0.25 ± 0.1 pg/mg                       0.9 ± 0.4 pg/mg                                                      Out of range
  Pre-eclampsia                                O11,O14                          P:USA (3--4% baby-delivery women)                        Diag                                                  P (9)                                                U                                     ELISA                                               N/A                                           N/A                                       A                             2.11 mg/mL                            0.014 mg/mL                                                 Within range after dilution
                                                                                                                                         Prog                                                  P (4)                                                U                                     ELISA                                              \~56%                                         \~73%                                      A                                 N/A                                   N/A                                                                 N/A
  Traumatic brain injury (TBI)                   S06                                P:USA (823.7 in 100,000)                             Prog                                                  P (1)                                                U                                     ELISA                                             90.00%                                        62.80%                                     A/C                            0.025 ng/mL                         0.02--1.35 ng/mL                                                     Out of range

(Diag, Prog, Br, F, Sa, Sk, Sp, T, U are the same as in [Table 3](#t3){ref-type="table"},Ther: Theragnostic, P: Protein, Sm: Small molecule, Pep: Peptide, miR: microRNA, CU: Clinical use, CT: Clinical trial, combi: combination, A: acute, C:Chronic).
